The FDA has approved a prefilled syringe option of Shingrix which will streamline administration of GSK’s herpes zoster ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

GSK (GSK) stock in focus as the U.S. FDA approves a new prefilled syringe presentation of its shingles vaccine, Shingrix.

The U.S. FDA has approved a prefilled syringe presentation of GSK plc’s SHINGRIX for the prevention of shingles.

The U.S. Food and Drug Administration approved a pre-filled syringe version of GSK's blockbuster shingles vaccine Shingrix, ...

The syringe removes the need to reconstitute separate vials prior to administration, which simplifies the vaccine administration process for healthcare professionals, GSK said Thursday. The existing ...

Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

The usually sluggish FTSE 100 is having a surprisingly good year. But our writer feels there are still potential bargains ...

GSK announces US FDA accepts application to review expanded use of RSV vaccine, Arexvy for adults 18-49 at increased risk: London, UK Wednesday, July 16, 2025, 14:00 Hrs [IST] GSK ...

Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

As FDA kicked off the drug user fee reauthorization process, Commissioner Marty Makary said he’d like to see lower fees paid ...